Morgado 2010.

Study characteristics
Methods	Study design: randomized controlled trial Study grouping: parallel group Loss to follow‐up: not reported Intention‐to‐treat: participants were analyzed in the groups to which they had been assigned Sample size estimation: not reported
Participants	Country: Portugal Setting: Hospital Pedro Hispano Enrollment date: not reported Baseline characteristics: not reported Topical mydriatics Number randomized: 30 Mean age, years (SD): 77.3 (NR) Women n (%): 20 (66.6) Race, n (%): not reported Preoperative pupillary diameter, mean, mm (SD): not reported Blood pressure, mean (SD): systolic 139.6 mmHg (16), diastolic 76.3 mmHg (9) Alpha‐adrenergic agonists, number (%): 3 (10) Pseudoexfoliation syndrome, number (%): 2 (6.6) Diabetes mellitus, number (%): 7 (23.3) Pre‐existing cardiac conditions, number (%): not reported Pre‐ and intraoperative NSAIDs at baseline, number (%): not reported Intracameral mydriatics Number randomized: 30 Mean age, years (SD): 79.3 (NR) Women n (%): 21 (70.0) Race, n (%): n (%): not reported Preoperative pupillary diameter, mean, mm (SD): not reported Blood pressure, mean (SD): systolic 138.5 mmHg (13), diastolic 77.7 mmHg (12) Alpha‐adrenergic agonists, number (%): 3 (10) Pseudoexfoliation syndrome, number (%): 3 (10.0) Diabetes mellitus, number (%): 9 (30.0) Pre‐existing cardiac conditions, number (%): not reported Pre‐ and intraoperative NSAIDs at baseline, number (%): not reported Depot delivery systems Number randomized: 30 Mean age, years (SD): 80.1 (NR) Women n (%): 22 (73.3) Race, n (%): not reported Preoperative pupillary diameter, mean, mm (SD): not reported Blood pressure, mean (SD): systolic 140.5 mmHg (18), diastolic 79.3 mmHg (11) Alpha‐adrenergic agonists, number (%): 2 (6.6) Pseudoexfoliation syndrome, number (%): 4 (13.3) Diabetes mellitus, number (%): 8 (26.6) Pre‐existing cardiac conditions, number (%): not reported Pre‐ and intraoperative NSAIDs at baseline, number (%): not reported Overall Number randomized: 90 Mean age, years (SD): not reported Women n (%): 63 (70.0) Race, n (%): not reported Preoperative pupillary diameter, mean, mm (SD): not reported Blood pressure, mean (SD): not reported Alpha‐adrenergic agonists, number (%): 8 (9) Pseudoexfoliation syndrome, number (%): 9 (10) Diabetes mellitus, number (%): 24 (27) Pre‐existing cardiac conditions, number (%): not reported Pre‐ and intraoperative NSAIDs at baseline, number (%): not reported Inclusion criteria: "Eyes with senile cataract undergoing phacoemulsification surgery" Exclusion criteria: "Eyes with iris posterior synechiae, prior eye surgery, and anterior segment malformation" Pretreatment: "Demographic data, comorbidities, and eye parameters were considered homogenous between groups"
Interventions	Topical mydriatics: "1% tropicamide and 10% phenylephrine drop, applied 3 times with 5‐minute intervals, initiated 60 minutes before surgery" Intracameral mydriatics: "Intracameral mydriasis with1% lidocaine (already performed in the anesthesia protocol) and 2.5% phenylephrine, administered into the anterior chamber, in a sequential manner (0.3 mL each drug)" Depot delivery systems: "Mydriasert mydriasis, with the device being placed in the inferior conjunctival sac, at least 1 hour before surgery. The insert contains 0.28 mg tropicamide and 5.4 mg phenylephrine hydrochloride equivalent to 1 0.5% tropicamide and 10% phenylephrine drop"
Outcomes	Primary: not reported Secondary: not reported Measured outcome: pupillary diameter at the beginning of procedure and at the end of procedure, intraoperative surgical time
Identification	Author name: Gabriel Morgado Institution: Department of Ophthalmology, Hospital Pedro Hispano, Porto, Portugal Email: gabrielmorgado@iol.pt Address: Rua do Monte 588 4405‐812 Vila Nova de Gaia Portugal Clinical Trials Registration Number: not reported
Notes	Sponsorship source: not reported Conflict of interest: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of random sequence generation not reported.
Allocation concealment (selection bias)	Unclear risk	Method of treatment allocation concealment not reported.
Masking of participants and personnel (performance bias)	Unclear risk	Masking of study participants and personnel not reported.
Masking of outcome assessment (detection bias)	Unclear risk	Masking of outcome assessors not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Participant attrition not reported, but number randomized is the same as number analyzed, and there is no evidence of participants lost to follow‐up.
Selective reporting (reporting bias)	Unclear risk	No trial registration; however, while outcomes specified in the methods section were reported in the results section, selective outcome reporting may still exist.